These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37774919)

  • 1. Complete response with sorafenib after immune-induced hepatitis with atezolizumab/bevacizumab for advanced hepatocellular carcinoma, synergic effect?
    Evain M; Galy-Fauroux I; Araujo-Goncalves J; Charlotte F; Couty JP; Allaire M
    Clin Res Hepatol Gastroenterol; 2023 Nov; 47(9):102210. PubMed ID: 37774919
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Hou Y; Wu B
    Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
    Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
    Minot-This MS; Edeline J
    Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
    [No Abstract]   [Full Text] [Related]  

  • 12. Systemic therapies in hepatocellular carcinoma: A revolution?
    Fortuny M; Sanduzzi-Zamparelli M; Reig M
    United European Gastroenterol J; 2024 Mar; 12(2):252-260. PubMed ID: 38267015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature.
    Ishikawa N; Kamimura K; Endo S; Ishii S; Ogawa K; Sakai N; Abe H; Ko M; Shibata O; Koseki Y; Yokoyama J; Sakamaki A; Terai S
    Intern Med; 2022 Nov; 61(21):3233-3237. PubMed ID: 35431306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
    An J; Han S; Kim HI; Shim JH
    Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
    N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports.
    Al Zahrani A; Alfakeeh A
    J Med Case Rep; 2021 Mar; 15(1):132. PubMed ID: 33722275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles.
    Boilève A; Smolenschi C; Fuerea A; Hollebecque A; Boige V
    Dig Liver Dis; 2021 Aug; 53(8):1059-1061. PubMed ID: 34030987
    [No Abstract]   [Full Text] [Related]  

  • 19. Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
    Castet F; Willoughby CE; Haber PK; Llovet JM
    Clin Cancer Res; 2021 Apr; 27(7):1827-1829. PubMed ID: 33472912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
    Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.